BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Entresto (Sacubitril/valsartan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Entresto (Sacubitril/valsartan)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06917664-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Entresto (Sacubitril/valsartan): Phase 4 readout est. (NCT06917664)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 4.\nStudy: Treatment of
  Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery D
 isease\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06917664
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04055428-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Entresto (Sacubitril/valsartan): Phase 2 readout est. (NCT04055428)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 2.\nStudy: NAUTICAL: Ef
 fect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Blac
 k Individuals\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04055428
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04971720-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Entresto (Sacubitril/valsartan): Phase 2/3 readout est. (NCT0497172
 0)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 2/3\, Hypertension.\nSt
 udy: PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP R
 hythm Axis\nEstimated primary completion: 1 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04971720
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05279742-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Entresto (Sacubitril/valsartan): Phase 1/2 readout est. (NCT0527974
 2)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 1/2\, Heart Failure.\nS
 tudy: Enhancing the Natriuretic Peptide System in HFpEF\nEstimated primary
  completion: April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacubitril-valsartan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05279742
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712030-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Entresto (Sacubitril/valsartan): Phase 3 readout est. (NCT06712030)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 3\, Heart Failure.\nStu
 dy: Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin 
 Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sacubitril-valsartan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06712030
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853625-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Entresto (Sacubitril/valsartan): Phase na readout est. (NCT07853625
 )
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase na\, Hypertension.\nStu
 dy: Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Inde
 x in Hypertensive Patients\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07853
 625
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05465031-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entresto (Sacubitril/valsartan): Phase 4 readout est. (NCT05465031)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 4\, Heart Failure.\nStu
 dy: Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Sy
 stematic breaST canceR trEAtMent (MAINSTREAM)\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sac
 ubitril-valsartan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05465031
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261098-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entresto (Sacubitril/valsartan): Phase 2 readout est. (NCT07261098)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 2\, Hypertension.\nStud
 y: The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer 
 With Concurrent Hypertension\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsar
 tan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07261098
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06655480-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entresto (Sacubitril/valsartan): Phase 2 readout est. (NCT06655480)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 2.\nStudy: Triple Combi
 nation Therapy (ARNI\, SGLT2i\, MRA) in Advanced HFpEF\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sacubitril-valsartan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06655480
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07572032-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280520
DTEND;VALUE=DATE:20280521
SUMMARY:Entresto (Sacubitril/valsartan): Phase 4 readout est. (NCT07572032)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 4\, Heart Failure.\nStu
 dy: Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected 
 Aetiology (DELAY-HF)\, Pilot Study\nEstimated primary completion: 20 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsa
 rtan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07572032
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856043-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Entresto (Sacubitril/valsartan): Phase 1 readout est. (NCT07856043)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 1\, Heart Failure.\nStu
 dy: [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduc
 ed Ejection Fraction\nEstimated primary completion: 30 June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07856043
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508035-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Entresto (Sacubitril/valsartan): Phase 3 readout est. (NCT05508035)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 3\, Heart Failure.\nStu
 dy: The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular
  Function and Remodeling in Patients With Ischemic Heart Failure With Mid-
 range Ejection Fraction\nEstimated primary completion: August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05508035
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06693674-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Entresto (Sacubitril/valsartan): Phase 3 readout est. (NCT06693674)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 3.\nStudy: Effect of Sa
 cubitril-Valsartan on Cardiac Structure and Function\nEstimated primary co
 mpletion: August 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacubitril-valsartan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06693674
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491718-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Entresto (Sacubitril/valsartan): Phase na readout est. (NCT07491718
 )
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase na.\nStudy: Manganese-e
 nhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy\nEstimated 
 primary completion: 9 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacubitril-valsartan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07491718
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05194111-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Entresto (Sacubitril/valsartan): Phase 1/2 readout est. (NCT0519411
 1)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 1/2\, Heart Failure.\nS
 tudy: Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril
 /Valsartan\nEstimated primary completion: 30 November 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05194111
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704633-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Entresto (Sacubitril/valsartan): Phase 4 readout est. (NCT06704633)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 4\, Heart Failure.\nStu
 dy: Sacubitril-valsartan in Patients With Heart Failure With Reduced Eject
 ion Fraction From Rural Tanzania\nEstimated primary completion: 30 Novembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacubitril-va
 lsartan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06704633
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910058-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Entresto (Sacubitril/valsartan): Phase 4 readout est. (NCT07910058)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 4\, Hypertension.\nStud
 y: Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibril
 lation Recurrence After Catheter Ablation in Persistent Atrial Fibrillatio
 n Patients With Without Hypertension\nEstimated primary completion: 31 Mar
 ch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacubitril-v
 alsartan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07910058
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631156-528@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Entresto (Sacubitril/valsartan): Phase 4 readout est. (NCT07631156)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 4\, Heart Failure.\nStu
 dy: STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in
  Normalized Heart Failure\nEstimated primary completion: 30 June 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763115
 6
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
